Fulcrum Therapeutics (NASDAQ:FULC) Issues Quarterly Earnings Results

Fulcrum Therapeutics (NASDAQ:FULC) issued its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03), Zacks reports.

Fulcrum Therapeutics Stock Down 3.9 %

Shares of Fulcrum Therapeutics stock opened at $3.70 on Tuesday. The company has a market capitalization of $199.57 million, a price-to-earnings ratio of -11.94 and a beta of 2.03. The stock’s 50-day simple moving average is $4.17 and its 200-day simple moving average is $4.66. Fulcrum Therapeutics has a 52 week low of $2.86 and a 52 week high of $13.70.

Wall Street Analysts Forecast Growth

FULC has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $9.33.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.